pubmed-article:15923160 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:15923160 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
pubmed-article:15923160 | lifeskim:mentions | umls-concept:C0370003 | lld:lifeskim |
pubmed-article:15923160 | lifeskim:mentions | umls-concept:C0034754 | lld:lifeskim |
pubmed-article:15923160 | lifeskim:mentions | umls-concept:C1441616 | lld:lifeskim |
pubmed-article:15923160 | lifeskim:mentions | umls-concept:C0162789 | lld:lifeskim |
pubmed-article:15923160 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
pubmed-article:15923160 | lifeskim:mentions | umls-concept:C1521871 | lld:lifeskim |
pubmed-article:15923160 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:15923160 | pubmed:dateCreated | 2005-5-30 | lld:pubmed |
pubmed-article:15923160 | pubmed:abstractText | We conducted this study to ascertain the prevalence of erb-b2 gene amplification in breast cancer specimens read as 2+ in immunohistochemical analysis. Slides from patients with metastatic or recurrent breast cancer were eligible for fluorescent in situ hybridization (FISH) study if they were read as 2+ immunohistochemically for erb-b2 by a certified pathologist. The PathVysion kit (Vysis, Downers Grove, IL) was used for FISH studies. Amplification of the erb-b2 gene was defined as an erb-b2/CEP17 (chromosome 17 centromere) ratio of 2 or more in 30 tumor cells counted. From May 2003 to June 2004, 221 slides were submitted from 24 hospitals around the island. Of 216 successful hybridizations, 96 (44.4%) were determined to be erb-b2 amplified. In addition, the topoisomerase IIa gene was coamplified in 11 (21%) of 53 and deleted in 8 (15%) of 53 erb-b2 amplified cases. The erb-b2 gene amplification rate was very high in cases determined to be 2+ by immunohistochemical analysis; therefore, determination of erb-b2 status by FISH in cases scored 2+ immunohistochemically is strongly recommended. | lld:pubmed |
pubmed-article:15923160 | pubmed:language | eng | lld:pubmed |
pubmed-article:15923160 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15923160 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:15923160 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15923160 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15923160 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15923160 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15923160 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15923160 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:15923160 | pubmed:month | Jul | lld:pubmed |
pubmed-article:15923160 | pubmed:issn | 0002-9173 | lld:pubmed |
pubmed-article:15923160 | pubmed:author | pubmed-author:LiuTsang-WuTW | lld:pubmed |
pubmed-article:15923160 | pubmed:author | pubmed-author:LiuJacqueline... | lld:pubmed |
pubmed-article:15923160 | pubmed:author | pubmed-author:LanChiehC | lld:pubmed |
pubmed-article:15923160 | pubmed:author | pubmed-author:ChenJim-RayJR | lld:pubmed |
pubmed-article:15923160 | pubmed:author | pubmed-author:PengJacquelin... | lld:pubmed |
pubmed-article:15923160 | pubmed:author | pubmed-author:HsuDer-HungDH | lld:pubmed |
pubmed-article:15923160 | pubmed:author | pubmed-author:LiangSuchingS | lld:pubmed |
pubmed-article:15923160 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:15923160 | pubmed:volume | 124 | lld:pubmed |
pubmed-article:15923160 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:15923160 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:15923160 | pubmed:pagination | 97-102 | lld:pubmed |
pubmed-article:15923160 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:meshHeading | pubmed-meshheading:15923160... | lld:pubmed |
pubmed-article:15923160 | pubmed:year | 2005 | lld:pubmed |
pubmed-article:15923160 | pubmed:articleTitle | erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. | lld:pubmed |
pubmed-article:15923160 | pubmed:affiliation | Division of Cancer Research, National Health Research Institutes, Taipei, Taiwan. | lld:pubmed |
pubmed-article:15923160 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:15923160 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:15923160 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15923160 | lld:pubmed |